Leishmaniasis (Visceral) Antibody, Serum
Use
Visceral leishmaniasis (kala azar) is a disseminated intracellular protozoal infection caused by Leishmania donovani, Leishmania chagasi, or Leishmania infantum, targeting primarily the reticuloendothelial system (liver, spleen, bone marrow). Transmission occurs through the bite of sandflies, with common symptoms including fever, weight loss, and splenomegaly. Pancytopenia and hypergammaglobulinemia are frequently present. This test detects antibodies to the recombinant K39 antigen of L. donovani as a sensitive method (95%-100%) for diagnosing active visceral leishmaniasis.
Special Instructions
Not provided.
Limitations
False-positive reactions may occur in patients with malaria or in the presence of rheumatoid factor. Patients coinfected with HIV and Leishmania may fail to produce antibodies, leading to false-negative results. Specimens containing glycerol or other viscous materials may affect the test. The test indicates only the presence of antibodies and should not be used as the sole criteria for diagnosing leishmaniasis.
FDA ApprovedNew York Approved
Methodology
Immunoassay (Lateral Flow)
Biomarkers
LOINC Codes
- 7958-2 - Leishmania Ab Ser Ql
- 7958-2 - Leishmania Ab Ser Ql
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.2 mL
Minimum Volume
0.1 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis, gross lipemia
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 14 days |
| Frozen | 14 days |